A 26-year-old was bloated and thought she had hemorrhoids. She was diagnosed with stage 4 colon cancer.

Mariana Tata experienced a few subtle, common symptoms of colon cancer and got them checked out. She was diagnosed at stage 4 ...

A simple blood test can predict Crohn's disease years before symptoms appear

Sinai Health researchers have shown a blood test that can predict Crohn's disease years before symptoms appear, opening the ...

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...

Crohn’s Disease May Be Detectable Years Before Symptoms

A blood test may detect Crohn’s disease years before it strikes—changing how the condition is predicted and prevented.
News-Medical.Net on MSN

Blood test opens the doors to early diagnosis and prevention of Crohn's disease

Sinai Health researchers have shown a blood test that can predict Crohn's disease years before symptoms appear, opening the ...

Spyre Therapeutics, Inc.: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

"6 in '26" expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ...

Microbially produced secondary bile acids accelerate colorectal cancer development, study shows

For the first time, a team of experts from the Technical University of Munich (TUM), RWTH Aachen University, and the German ...

Simple blood test can detect debilitating bowel disease years before any symptoms develop

A simple blood test can predict who will suffer from a debilitating bowel disease later in life, paving the way for early ...

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...
Le Lézard

PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator ...
Cantech Letter

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across ...